287 related articles for article (PubMed ID: 6574695)
1. Tetrabenazine in the treatment of hyperkinetic movement disorders.
Jankovic J
Adv Neurol; 1983; 37():277-89. PubMed ID: 6574695
[No Abstract] [Full Text] [Related]
2. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
Kenney C; Hunter C; Jankovic J
Mov Disord; 2007 Jan; 22(2):193-7. PubMed ID: 17133512
[TBL] [Abstract][Full Text] [Related]
3. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
Chen JJ; Ondo WG; Dashtipour K; Swope DM
Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
[TBL] [Abstract][Full Text] [Related]
4. Analysis of CYP2D6 genotype and response to tetrabenazine.
Mehanna R; Hunter C; Davidson A; Jimenez-Shahed J; Jankovic J
Mov Disord; 2013 Feb; 28(2):210-5. PubMed ID: 23280482
[TBL] [Abstract][Full Text] [Related]
5. Tetrabenazine in the treatment of hyperkinetic movement disorders.
Kenney C; Jankovic J
Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study.
Jankovic J
Ann Neurol; 1982 Jan; 11(1):41-7. PubMed ID: 6460467
[TBL] [Abstract][Full Text] [Related]
7. Tetrabenazine therapy of pediatric hyperkinetic movement disorders.
Jain S; Greene PE; Frucht SJ
Mov Disord; 2006 Nov; 21(11):1966-72. PubMed ID: 16958131
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic use of tetrabenazine].
López Del Val LJ; López-García E; Martínez-Martínez L; Santos-Lasaosa S
Rev Neurol; 2009 May 16-31; 48(10):523-33. PubMed ID: 19434587
[TBL] [Abstract][Full Text] [Related]
9. [Hyperkinetic syndromes. Therapeutic trials].
Severini P; Pompili A; Pierini G
Riv Neurol; 1978; 48(2):242-8. PubMed ID: 276041
[TBL] [Abstract][Full Text] [Related]
10. Drug treatment of diseases characterized by abnormal movements.
Marsden CD
Proc R Soc Med; 1973 Sep; 66(9):871-3. PubMed ID: 4281483
[No Abstract] [Full Text] [Related]
11. [Movement abnormalities and their treatment in general practice].
Gonce M; Delwaide PJ
Rev Med Liege; 1979 Oct; 34(19):797-802. PubMed ID: 297251
[No Abstract] [Full Text] [Related]
12. Tetrabenazine and movement disorders.
Asher SW; Aminoff MJ
Neurology; 1981 Aug; 31(8):1051-4. PubMed ID: 6455607
[TBL] [Abstract][Full Text] [Related]
13. Tetrabenazine treatment in movement disorders.
Paleacu D; Giladi N; Moore O; Stern A; Honigman S; Badarny S
Clin Neuropharmacol; 2004; 27(5):230-3. PubMed ID: 15602104
[TBL] [Abstract][Full Text] [Related]
14. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
Guay DR
Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for tolerability of tetrabenazine in patients with hyperkinetic movement disorders.
Sahin T; Yilmaz R; Akbostanci MC
Parkinsonism Relat Disord; 2020 May; 74():36-37. PubMed ID: 32311641
[No Abstract] [Full Text] [Related]
16. Movement disorders in the elderly.
Gilmore R
Geriatrics; 1984 Jun; 39(6):65-8, 72-6. PubMed ID: 6144615
[No Abstract] [Full Text] [Related]
17. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
Paton DM
Drugs Today (Barc); 2017 Feb; 53(2):89-102. PubMed ID: 28387387
[TBL] [Abstract][Full Text] [Related]
18. Drug treatment of hyperkinetic movement disorders.
Fahn S
Semin Neurol; 1987 Jun; 7(2):192-208. PubMed ID: 3332454
[No Abstract] [Full Text] [Related]
19. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.
Jankovic J; Orman J
Neurology; 1988 Mar; 38(3):391-4. PubMed ID: 3279337
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of tetrabenazine in hyperkinetic movement disorders.
Jankovic J; Beach J
Neurology; 1997 Feb; 48(2):358-62. PubMed ID: 9040721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
